Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Compugen Earns $6M AstraZeneca Milestone in Antibody Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Compugen Earns $6M AstraZeneca Milestone in Antibody Alliance

First patient dosed in Phase 1/2 study of AZD2936 in advanced or metastatic non-small cell lung cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Compugen Ltd., a clinical-stage cancer immunotherapy company will receive a $6 million milestone payment from AstraZeneca triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902, Compugen’s high-affinity clinical-stage anti-TIGIT antibody.
 
“We are proud that AstraZeneca’s TIGIT bispecific program, derived from COM902, has advanced to the clinic and become our fourth clinical stage program originating from our innovative pipeline” said Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen. “We hope COM902’s differentiated properties will contribute to the clinical success of AZD2936 and we look forward to the advancement of this important clinical program.”
 
The companies entered an agreement in 2018 under which Compugen provided an exclusive license to AstraZeneca to use its monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody products. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license.
 
To date, Compugen has also received a $10 million upfront payment, an additional $2 million milestone payment, and is eligible for as much as $200 million in development, regulatory and commercial milestones for the first product, as well as royalties on sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics